In the latest of phraktion's Peer-to-Peer webinar series featuring pharma industry leaders, we were joined by phraktion partner, Dr Ornah Levine-Dolberg.
In an industry where commercial success hinges on scientific validation, medical affairs stand as the critical link between the lab and the market.
That's where Med Affairs Alchemy comes in.
A tested methodology for architecting a tailored medical affairs operating model that resonates across the entire business spectrum. Whether you're a multinational pharmaceutical titan or a upstart biotech pioneer, a lean team or a fully-built department, Med Affairs Alchemy gives you the tools to construct a best-in-class framework that extracts maximum commercial value from your scientific excellence.
With Med Affairs Alchemy, you have the architect's blueprint for building the optimal cross-functional bridge - one that demonstrably conveys your scientific strengths as mission-critical drivers of business performance. Implement these tools and watch as your commercial counterparts finally grasp and champion the immense value you bring to your company's success.
Ornah Levine-Dolberg is a specialist in psychiatry whose nearly 30-year career has spanned both clinical practice and the pharmaceutical industry. Her comprehensive experience ranges from research and development to all facets of medical affairs on a country, regional and global level.
A proven launch expert, Ornah was instrumental in the rollout of a triple-blockbuster drug, spearheading successful commercialisation strategies in key markets like China and South Korea. She has held prestigious leadership roles in the medical affairs branches of multiple multinational pharma companies over the past decade.
Ornah's diverse first-hand experience has given her unparalleled cross-functional fluency spanning R&D, medical, commercial, and corporate operations. She is a true master at the "alchemy" of extracting maximum value from scientific data and positioning medical affairs as an integral driver of business performance.
